BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

ABCL

AbCellera Biologics Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$4M−76.3% year on year
$400M$200M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$120M+29.9% year on year
$1B$500M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$120M
$400M$200M$0−$200M
Q4 ’21Q1 ’23Q1 ’24Q2 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty